PLATINUM-BASED CHEMOTHERAPY FOLLOWED BY RADIATION-THERAPY OF LOCALLY ADVANCED NASOPHARYNGEAL CANCER - A RETROSPECTIVE ANALYSIS OF 39 CASES

被引:20
|
作者
FOUNTZILAS, G
DANIILIDIS, J
KOSMIDIS, P
SRIDHAR, KS
KALOGERAFOUNTZILA, A
NICOLAOU, A
MAKRANTONAKIS, P
BANIS, K
DIMITRIADIS, A
SOMBOLOS, K
ZARAMBOUKAS, T
THEMELIS, C
VRITSIOS, A
TOURKANTONIS, A
机构
[1] AHEPA UNIV HOSP, DEPT INTERNAL MED, Thessaloniki, GREECE
[2] AHEPA UNIV HOSP, DEPT OTORHINOLARYNGOL, Thessaloniki, GREECE
[3] AHEPA UNIV HOSP, DEPT RADIOL, Thessaloniki, GREECE
[4] AHEPA UNIV HOSP, DEPT RADIAT THERAPY, Thessaloniki, GREECE
[5] AHEPA UNIV HOSP, DEPT PATHOL, Thessaloniki, GREECE
[6] METAXA CANC HOSP, DEPT MED ONCOL, PIRAEAUS, GREECE
[7] METAXA CANC HOSP, DEPT OTORHINOLARYNGOL, PIRAEAUS, GREECE
[8] MIAMI SCH MED, SYLVESTER COMPREHENS CANC CTR, MIAMI, FL USA
[9] VA HOSP, MIAMI, FL USA
关键词
NASOPHARYNGEAL CANCER; CHEMOTHERAPY; PLATINUM-BASED; RADIOTHERAPY;
D O I
10.3109/02841869109091830
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective analysis was performed of 39 patients with locally advanced nasopharyngeal cancer treated with combined chemotherapy and radiation therapy during the last five years at our departments. There were 26 men and 13 women with median age 55 (24-75) years. Histology was squamous cell carcinoma in 6 patients and undifferentiated carcinoma in the remaining 33 patients. Induction chemotherapy consisted of either regimen A (cisplatin 100 mg/m2 day 1, 5-FU 1 000 mg/m2 days 2-6 as continuous infusion, bleomycin 15 mg days 15 and 29 i.m., mitomycin 4 mg/m2 day 22 and hydroxyurea 1 000 mg/m2 daily days 23-27) or regimen B (carboplatin 300 mg/m2 day 1, 5-FU 1 000 mg/m2 days 1-5 as continuous infusion and methotrexate 1.2 g/m2 day 14 with leucovorin rescue). After completion of induction chemotherapy 13 patients (33%) had complete remission (CR) and 19 (49%) partial remission (PR). The CR rate was increased after radiation therapy to 72%. Survival rates were 88% at 12 and 78% at 24 months. Median time to progression was 29.5 months. In conclusion, induction chemotherapy with a platinum-based regimen followed by radiation therapy achieved a high rate of local control. If the treatment also prolongs survival must, however, be studied by randomized trials.
引用
收藏
页码:831 / 834
页数:4
相关论文
共 50 条
  • [31] Treatment on advanced NSCLC: Platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials
    Zhou, Jian-Guo
    Tian, Xu
    Wang, Xue
    Tian, Jin-Hui
    Wang, Yi
    Wang, Fei
    Zhang, Yu
    Ma, Hu
    MEDICAL ONCOLOGY, 2015, 32 (02)
  • [32] A Retrospective Study of Patients With Locally Advanced Cancer of the Cervix Treated With Neoadjuvant Chemotherapy Followed by Radical Surgery
    Kumar, Jaggi Vinita
    Doval, D. C.
    Rao, Ranga
    Rawal, Sudhir
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (03) : 417 - 422
  • [33] Efficacy of intraarterial chemoinfusion therapy for locally advanced breast cancer patients: a retrospective analysis of 28 cases
    Zhang, Wei
    Liu, Rong
    Wang, Yingying
    Qian, Sheng
    Wang, Jianhua
    Yan, Zhiping
    Zhang, Hongwei
    ONCOTARGETS AND THERAPY, 2013, 6 : 761 - 765
  • [34] Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer
    Einerhand, Sarah M. H.
    van Dijk, Nick
    van Dorp, Jeroen
    de Feijter, Jeantine M.
    van Montfoort, Maurits L.
    van de Kamp, Maaike W.
    Schaake, Eva E.
    Boellaard, Thierry N.
    Hendricksen, Kees
    van der Heijden, Michiel S.
    van Rhijn, Bas W. G.
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (11) : 2004 - 2011
  • [35] Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma
    Hosogoe, Shogo
    Hatakeyama, Shingo
    Kusaka, Ayumu
    Hamano, Itsuto
    Iwamura, Hiromichi
    Fujita, Naoki
    Yamamoto, Hayato
    Tobisawa, Yuki
    Yoneyama, Tohru
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ohyama, Chikara
    EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 946 - 953
  • [36] PREOPERATIVE CHEMOTHERAPY AND RADIATION-THERAPY FOR LOCALLY ADVANCED PRIMARY AND RECURRENT RECTAL-CARCINOMA - A REPORT OF SURGICAL MORBIDITY
    SHUMATE, CR
    RICH, TA
    SKIBBER, JM
    AJANI, JA
    OTA, DM
    CANCER, 1993, 71 (11) : 3690 - 3699
  • [37] Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
    Silva, Saulo Brito
    Lima Pereira, Allan Andresson
    Marta, Gustavo Nader
    Lopes de Barros Lima, Kennya Medeiros
    de Freitas, Thiago Brasileiro
    Brandao Matutino, Adriana Reis
    Leonardi de Azevedo Souza, Manoel Carlos
    Meira Velame de Azevedo, Renata Gondim
    Hermida de Viveiros, Pedro Antonio
    da Silva Lima, Julianne Maria
    Filassi, Jose Roberto
    Carvalho, Heloisa de Andrade
    Morales Piato, Jose Roberto
    Mano, Max S.
    BREAST, 2018, 38 : 39 - 44
  • [38] Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer
    Magnino, A
    Gatti, M
    Massucco, P
    Sperti, E
    Faggiuolo, R
    Regge, D
    Capussotti, L
    Gabriele, P
    Aglietta, M
    ONCOLOGY, 2005, 68 (4-6) : 493 - 499
  • [39] Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer
    Muto, Satoru
    Abe, Hideyuki
    Noguchi, Takahiro
    Sugiura, Sho-ichiro
    Kitamura, Kousuke
    Isotani, Shuji
    Ide, Hisamitsu
    Yamaguchi, Raizo
    Kamai, Takao
    Horie, Shigeo
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (05) : 490 - 494
  • [40] Concurrent chemoradiotherapy followed by adjuvant chemotherapy compared with concurrent chemoradiotherapy alone for the treatment of locally advanced nasopharyngeal carcinoma: a retrospective controlled study
    Liang, Z.
    Zhu, X.
    Li, L.
    Qu, S.
    Liang, X.
    Liang, Z.
    Su, F.
    Li, Y.
    Zhao, W.
    CURRENT ONCOLOGY, 2014, 21 (03) : E408 - E417